Robert Chess
Director · NEKTAR THERAPEUTICS
IndividualSelling only14 10b5-1 trades
- 2024
- Sep 26, 2026
- 8
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Robert Chess files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Emily M. Leproust - $101.55M in TWST purchases and sales in the last 12 months
- Patrick John Finn - $21.57M in TWST purchases and sales in the last 12 months
- Dennis Cho - $8.78M in TWST purchases and sales in the last 12 months
- Paula Green - $7.22M in TWST purchases and sales in the last 12 months
- Adam Laponis - $4.09M in TWST purchases and sales in the last 12 months
- Robert F. Werner - $1.49M in TWST purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Robert Chess?
Robert Chess is a corporate insider, tracked as Director of NEKTAR THERAPEUTICS (NKTR). InsiderAlpha holds 8 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Robert Chess submitted recently?
2 primary Form 4 filings in the last 90 days, covering 2 companies.
Has Robert Chess been buying or selling stock?
Recorded transactions: 0 open-market purchases and 7 open-market sales ($2.97M) across all tracked filings.
